#

+91-9811715635

  • #
  • #
  • #
#

Pharma & Healthcare

Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)

Price: US$ 800.00 | Pages : 59 | Publish Date : Dec 2016

Improvement in the method of treatment is the major driver for the growth of the market, a number of technologies and diagnostics have been innovated to treat and diagnose the same. Thus, the increased awareness along with improved treatment signifies the upsurge in the AAT Replacement Therapy marke...

Detail...

Global Aesthetic Market: With Focus on Aesthetic Injectables Market (2016-2020)

Price: US$ 850.00 | Pages : 65 | Publish Date : Dec 2016

The global aesthetic market increased at a significant CAGR during the span of 5 years, i.e., 2011-2015 and projections are made that the market would rise in the next five years, i.e., 2016-2020 tremendously. The market is spread across the globe with the North America dominating the market with mo...

Detail...

Global Wound Care Market: Size, Trends & Forecasts (2016-2020)

Price: US$ 800.00 | Pages : 61 | Publish Date : Dec 2016

Wound care is defined as the process through which it is taken care that the wounds do not reach a stage where they become completely untreatable and develop complications. Wound care can be done naturally when the wound heals in accordance with the healing capacity of the body. Also, wounds get hea...

Detail...

Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)

Price: US$ 900.00 | Pages : 85 | Publish Date : Nov 2016

Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that trigg...

Detail...

Global Biosimilar Market: Size, Trends & Forecasts (2016-2020)

Price: US$ 800.00 | Pages : 58 | Publish Date : Nov 2016

Majority of biosimilars are in pipeline as most of the major biologics have either already expired or are about to lose their patent in the next two years which act as a major driving force for the biosimilar market. Four major biologics namely Humira, Enbrel, Remicade and Infliximab patents are set...

Detail...